文献速递慢阻肺呼吸道感染

上呼吸道感染起病时强化ICS/LABA治疗预防慢阻肺急性加重:多中心随机双盲安慰剂对照试验

Intensified Therapy with Inhaled Corticosteroids and Long-Acting β2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该多中心随机双盲安慰剂对照试验纳入450例稳定期中重度至极重度慢阻肺患者,在出现上呼吸道感染症状时启动10天强化剂量ICS/LABA或安慰剂治疗。结果显示强化治疗未显著降低任何急性加重发生率(14.6% vs 16.2%),但严重急性加重风险降低72%(HR 0.28,95%CI 0.11-0.74,P=0.010)。

要点

  • 上呼吸道感染起病时强化ICS/LABA 10天未降低总体急性加重发生率
  • 严重急性加重风险降低72%(HR 0.28,95%CI 0.11-0.74,P=0.010)
  • 疾病更严重患者任何急性加重风险显著降低

核心结论

  • 上呼吸道感染起病时强化ICS/LABA治疗10天未降低任何慢阻肺急性加重发生率,但预防了严重急性加重。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,纳入450例稳定期中重度至极重度慢阻肺患者。
  • 入组时均接受开放标签低维持剂量ICS/LABA,随机分配至强化剂量ICS/LABA或安慰剂,仅在上呼吸道感染症状起病时每日两次使用10天。

主要发现

  • 上呼吸道感染后任何急性加重发生率在ICS/LABA组与安慰剂组分别为14.6% vs 16.2%(HR 0.77,95%CI 0.46-1.33,P=0.321),无显著降低。
  • 严重急性加重风险降低72%(HR 0.28,95%CI 0.11-0.74,P=0.010)。
  • 分层分析显示疗效受疾病严重程度、呼出气一氧化氮、BMI-气流阻塞-呼吸困难-运动评分修饰。
  • 与稳定期相比,上呼吸道感染时、感染后10天及急性加重时至少检出一种病毒的比例显著更高。

关键数值与推荐

  • 任何急性加重发生率:14.6% vs 16.2%(HR 0.77,95%CI 0.46-1.33,P=0.321)。
  • 严重急性加重:HR 0.28(95%CI 0.11-0.74,P=0.010),风险降低72%。

临床怎么用

  • 慢阻肺患者在上呼吸道感染症状起病时启动10天强化ICS/LABA治疗不能减少总体急性加重,但可显著降低严重急性加重风险。
  • 疾病更严重患者可能从该策略中获得任何急性加重的风险降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: The efficacy of intensified combination therapy with inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) at the onset of upper respiratory tract infection (URTI) symptoms in chronic obstructive pulmonary disease (COPD) is unknown. OBJECTIVES: To evaluate whether intensified combination therapy with ICS/LABA, at the onset of URTI symptoms, decreases the incidence of COPD exacerbation occurring within 21 days of the URTI. METHODS: A total of 450 patients with stable, moderate to very severe COPD, were included in this investigator-initiated and -driven, double-blind, randomized, placebo-controlled study. At inclusion, patients were assigned to open-labeled low-maintenance dose ICS/LABA. Each patient was randomized either to intensified-dose ICS/LABA or placebo and instructed to start using this medication only in case of a URTI, at the onset of symptoms, twice daily, for 10 days. MEASUREMENTS AND MAIN RESULTS: The incidence of any exacerbation following a URTI was not significantly decreased in the ICS/LABA group, as compared with placebo (14.6% vs. 16.2%; hazard ratio, 0.77; 95% confidence interval, 0.46-1.33; P = 0.321) but the risk of severe exacerbation was decreased by 72% (hazard ratio, 0.28; 95% confidence interval, 0.11-0.74%; P = 0.010). In the stratified analysis, effect size was modified by disease severity, fractional exhaled nitric oxide, and the body mass index-airflow obstruction-dyspnea, and exercise score. Compared with the stable period, evidence of at least one virus was significantly more common at URTI, 10 days after URTI, and at exacerbation. CONCLUSIONS: Intensified combination therapy with ICS/LABA for 10 days at URTI onset did not decrease the incidence of any COPD exacerbation but prevented severe exacerbation. Patients with more severe disease had a significant risk reduction for any exacerbation. Clinical trial registered with www.isrctn.com (ISRCTN45572998).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Stolz D, Hirsch HH, Schilter D, et al. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2018. PMID: 29266965. doi:10.1164/rccm.201709-1807OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。